Background It is largely unknown how frequently low-abundance HIV drug-resistant variants
at levels under limit of detection of conventional genotyping (< 20% of quasi-species) are …

Background Transmitted HIV-1 drug resistance can compromise initial antiretroviral therapy
(ART); therefore, its detection is important for patient management. The absence of drug …

Background. The prevalence of drug resistance among persons with newly acquired human
immunodeficiency virus (HIV) infection is well documented. However, it is unclear to what …

Several prospective and retrospective studies have shown that genotypic testing for drug-
resistant HIV-1 variants has helped health-care providers better understand patient …

Abstract Background Minor (ie,< 20% prevalence) drug-resistant human immunodeficiency
virus (HIV) variants may go undetected, yet be clinically important Objectives To compare …

Background: Transmission of drug-resistant HIV strains to antiretroviral therapy (ART)-naïve
subjects can negatively impact therapy response. As treatment strategies and utilization of …

Objectives A major barrier to successful viral suppression in HIV type 1 (HIV-1)-infected
individuals is the emergence of virus resistant to antiretroviral drugs. We explored the …

Objective: To estimate the prevalence of HIV drug resistance over time and identify risk
factors for multiclass resistance. Design: Prospective clinical cohort of HIV-infected patients …

Context Presence of low-frequency, or minority, human immunodeficiency virus type 1 (HIV-
1) drug resistance mutations may adversely affect response to antiretroviral treatment (ART) …

Objective To investigate the distribution of drug-resistant HIV-1 variants in plasma RNA and
peripheral blood monuclear cell (PBMC) DNA at treatment failure while on therapy and after …